<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03276988</url>
  </required_header>
  <id_info>
    <org_study_id>GX30_P1/2</org_study_id>
    <nct_id>NCT03276988</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients</brief_title>
  <official_title>A Prospective, Open-label, Dose Escalation, (Phase 1); Prospective, Randomized, Evaluator Blinded, Active-controlled, 2-sequence, 2-period, 2-treatment, Crossover (Phase 2); Phase 1/2 Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, Safety and Efficacy of GX-30 Administered Intramuscularly in Patients Underwent Total Thyroidectomy or Near Total Thyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symyoo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and pharmacokinetics in
      patients with total thyroidectomy or near total thyroidectomy of an investigational rhTSH
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant human TSH was developed to provide TSH stimulation without withdrawal of thyroid
      hormone. Radioiodine ablation and diagnosis with rhTSH became standard of care treatment for
      patients with differentiated thyroid cancer. Stably supplying rhTSH has been the unmet need
      for management and follow-up procedure for thyroid remnant. GX-30 is an investigational
      product, developed to provide inexpensive rhTSH to patients in order to ensure stable supply
      of rhTSH.

      The purpose of this study is to assess tolerability of GX-30, in patients with total
      thyroidectomy or near total thyroidectomy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 11, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose level 1 : GX-30 0.45mg
Dose level 2 : GX-30 0.9mg
Dose level 3 : GX-30 0.9mg x 2 times</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>through study completion, an average of 6 months.</time_frame>
    <description>Maximum Tolerant Dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TSH concentration</measure>
    <time_frame>through study completion, an average of 6 months.</time_frame>
    <description>TSH concentration for Pharmacokinetics assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-TSH concentration</measure>
    <time_frame>through study completion, an average of 6 months.</time_frame>
    <description>Anti-TSH concentration for Anti-Drug Antibody detection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Total Thyroidectomy</condition>
  <condition>Near Total Thyroidectomy</condition>
  <arm_group>
    <arm_group_label>Dose level 1 (GX-30 0.45mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GX-30 0.45mg, Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2 (GX-30 0.9mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GX-30 0.9mg, Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3 (GX-30 0.9mg x 2 times)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GX-30 0.9mg, Intramuscular injection
Administration of GX-30 0.9mg, Intramuscular injection, 24h after the first injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-30 0.45mg IM</intervention_name>
    <description>GX-30 0.45mg administered in the gluteal muscle.</description>
    <arm_group_label>Dose level 1 (GX-30 0.45mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-30 0.9mg IM</intervention_name>
    <description>GX-30 0.9mg administered in the gluteal muscle.</description>
    <arm_group_label>Dose level 2 (GX-30 0.9mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-30 0.9mg x 2 times IM</intervention_name>
    <description>First injection: GX-30 0.9mg administered in the gluteal muscle Second injection : GX-30 0.9mg administered in the gluteal muscle 24 hour after the first injection</description>
    <arm_group_label>Dose level 3 (GX-30 0.9mg x 2 times)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who voluntarily consented, after listing enough explanation for this study
             and investigational product.

          -  Minimum 19 years old.

          -  Minimum 50kg of body weight.

          -  Patients with total thyroidectomy or near total thyroidectomy due to non-malignant
             thyroid tumor

          -  Patients with thyroidectomy or near total thyroidectomy due to differentiated thyroid
             carcinoma.

          -  Patient undergoing thyroid hormone administration.

        Exclusion Criteria:

          -  Thyroid cancer excluding differentiated thyroid carcinoma.

          -  Thyroidectomy excluding total thyroidectomy and near total thyroidectomy.

          -  Patients with heart, renal, or liver failure.

          -  Patients with ischemic stroke or the history of ischemic stroke.

          -  Smoker or Ex-smoker with less than 3 months of stopping

          -  Patients with migraine or the history of migraine.

          -  Patients that the researchers do not think fit into the group, including patients
             failed in compliance assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Ability to avoid pregnancy during and after the trial: Women physically capable of pregnancy must avoid pregnancy during ongoing period and 6 months after injection. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), or use of acceptable contraception: hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD).</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mu Il Kang, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gyu Tae Kim</last_name>
    <phone>+82-70-4335-5447</phone>
    <email>gtkim@symyoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun Jung Kim</last_name>
    <phone>+82-31-628-3353</phone>
    <email>yjkim@genexine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shin Gon Kim, M.D., Ph. D.</last_name>
      <phone>+82-2-920-5890</phone>
      <email>k50367@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Shin Gon Kim, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Jun Lim, M.D.</last_name>
      <phone>+82-2-2258-6009</phone>
      <email>ldj6026@naver.com</email>
    </contact>
    <investigator>
      <last_name>Dong Jun Lim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://synapse.koreamed.org/DOIx.php?id=10.7599/hmr.2012.32.4.187</url>
    <description>Park DJ. Thyroid and Hydrogen Peroxide. Hanyang Med Rev 2012;32:187-91</description>
  </link>
  <link>
    <url>https://www.sanofigenzyme.co.kr/Products/Thyrogen.aspx</url>
    <description>Genzyme Thyrogen</description>
  </link>
  <reference>
    <citation>Goel R, Raju R, Maharudraiah J, Sameer Kumar GS, Ghosh K, Kumar A, Lakshmi TP, Sharma J, Sharma R, Balakrishnan L, Pan A, Kandasamy K, Christopher R, Krishna V, Mohan SS, Harsha HC, Mathur PP, Pandey A, Keshava Prasad TS. A Signaling Network of Thyroid-Stimulating Hormone. J Proteomics Bioinform. 2011 Oct 29;4. doi: 10.4172/jpb.1000195.</citation>
    <PMID>24255551</PMID>
  </reference>
  <reference>
    <citation>Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994 Jan;78(1):188-96.</citation>
    <PMID>8288703</PMID>
  </reference>
  <reference>
    <citation>Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab. 2001 Apr;86(4):1660-4.</citation>
    <PMID>11297600</PMID>
  </reference>
  <reference>
    <citation>Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997 Sep 25;337(13):888-96.</citation>
    <PMID>9302303</PMID>
  </reference>
  <reference>
    <citation>Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov;84(11):3877-85.</citation>
    <PMID>10566623</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid cancer</keyword>
  <keyword>Thyroidectomy</keyword>
  <keyword>rhTSH</keyword>
  <keyword>GX-30</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

